Biopharmaceutical company TopoTarget receives major investment  

2005.03.18
The Anglo-Danish company has gained a DKK 110 mn investment from existing investors BankInvest and HealthCap, and a new investor, Deutsche Venture Capital

TopoTarget, a Danish biopharmaceutical company which develops new and improved drugs for the treatment of cancer, has gained a DKK 110 mn (USD 19.8 mn) investment from existing investors BankInvest and HealthCap, and a new investor, Deutsche Venture Capital. The investment will be used for the clinical development of TopoTarget's drug candidates. The company's first product launch is scheduled for 2006.

 

Earlier this month, TopoTarget acquired G2M Cancer Drugs AG, a German biopharmaceutical company which develops novel anti-cancer therapeutics. Following the acquisition, TopoTarget has six drugs in clinical trials. The news is reported by financial daily newspaper Børsen and on TopoTarget's website.

 

TopoTarget is an Anglo-Danish company founded in 2000 through a merger between the UK cell cycle company Profilix and the Danish oncology company TopoTarget. It is based in Symbion Science Park, Copenhagen, Oxford, UK, and Frankfurt, Germany.

 

Link > TopoTarget 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×